Objective Subantimicrobial-dose doxycycline (SDD) treatment has been reported to reduce the severity of chronic inflammation and to increase serum high-density lipoprotein cholesterol. In a double-blind, placebo-controlled clinical trial, we determined whether SDD affects the ability of serum to facilitate cholesterol removal from macrophages. Methods Forty-five postmenopausal osteopenic women with periodontitis were randomly assigned to take placebo (n = 26) or doxycycline hyclate (20 mg, n = 19) tablets twice daily for 2 years. Serum samples were collected at baseline, 1-, and 2-year appointments. The cholesterol efflux capacity of serum from cultured human macrophages (THP-1) was measured. Results SDD subjects demonstrated a significant increase in serum-mediated cholesterol efflux from macrophages at both time points compared to baseline (p \ 0.04 for each). Mean cholesterol efflux levels over the first year of followup were 3.0 percentage points (unit change) higher among SDD subjects compared to placebo subjects (p = 0.010), while there was no significant difference in 2-year changes. There were no significant differences in the changes of apolipoprotein A-I, apolipoprotein A-II, or serum amyloid A levels between the groups. Conclusions Our results suggest that SDD treatment may reduce the risk of cardiovascular disease in this patient group by increasing the cholesterol efflux capacity of serum.
Introduction
Periodontitis is a bacterial infection of the tooth-supporting tissues leading to chronic inflammation. It is one of the most common chronic inflammatory diseases in the adult population; a recent study from the United States revealed that 47 % of adults have periodontitis, and of adults aged 65 years and older, 64 % suffer from moderate or severe periodontitis [1] . According to present knowledge, chronic periodontitis is associated with an increased risk of atherosclerotic coronary artery disease (CAD), although a causal relationship has not yet been proven [2] .
As a systemic response to periodontitis, patients suffer from low-grade chronic inflammation and display elevated serum levels of inflammatory biomarkers, such as C-reactive protein (CRP), interleukin-6 (IL-6) [3, 4] , and matrix metalloproteinases (MMPs) [5] . These inflammatory mediators are also regarded as biomarkers of CAD risk [6] .
Decreased serum high-density lipoprotein (HDL) cholesterol concentration is a significant independent risk factor for CAD. Low levels of HDL cholesterol and apolipoprotein A-I (apoA-I), the major protein component of HDL particles, have been associated with CAD incidence in numerous studies [7] . Among the several anti-atherogenic properties of HDL, the major one is considered to be its ability to facilitate the efflux of cholesterol from macrophage foam cells in the arterial walls. Cholesterol efflux from cell membranes is the first and rate-limiting step of reverse cholesterol transport, the process in which excess cholesterol is transported from peripheral tissues back to the liver for excretion. According to in-vitro studies, proinflammatory factors such as bacterial endotoxins, tumor necrosis factor-alpha (TNF-a), and IL-1b may impair cholesterol efflux from macrophages and reverse cholesterol transport [8] . Inflammation, including periodontitis, is associated with low serum HDL cholesterol concentration and an altered HDL composition [9] . The changes in HDL composition, especially replacement of apoA-I with serum amyloid A (SAA), induced by inflammation may affect the cholesterol efflux capacity of HDL particles. The exact mechanisms, however, that generate the low HDL cholesterol profile during inflammation remain unclear.
Tetracyclines, in addition to their antimicrobial properties, also have immunomodulatory and anti-proteolytic effects [10] at both regular and low (sub-antimicrobial) concentrations [11] . Subantimicrobial-dose doxycycline (SDD) treatment has been shown to reduce the severity of chronic inflammatory disorders such as periodontitis [12] and rheumatoid arthritis [13] . A meta-analysis of seven human studies indicated that, in addition to conventional periodontal therapy, the use of SDD demonstrated a significant positive effect in the treatment of chronic periodontitis [14] . SDD reduced high sensitivity (hs)-CRP and IL-6 levels in plasma as well as MMP-9 activity in patients with acute coronary syndrome [15] . SDD increased serum HDL cholesterol and apoA-I levels in a 6-week trial of 36 patients [16] . SDD also significantly decreased MMP-9 and hs-CRP levels in post-menopausal osteopenic women with periodontitis, and increased HDL cholesterol among the subgroup of women more than 5 years postmenopausal [17] .
With this background, our aim was to examine the effect of SDD therapy on the cholesterol efflux capacity of serum samples derived from a group of postmenopausal, osteopenic women with chronic periodontitis. The patients were at risk of developing CAD, but they had no history of myocardial infarction, angina, or stroke. The data from this study represent secondary outcomes from a subgroup of patients who participated in a placebo-controlled, doubleblind randomized clinical trial.
Methods

Study subjects
The details of the clinical trial and sample size estimation have been described earlier [18] . Briefly, the subjects were postmenopausal osteopenic females 45-70 years of age, and not receiving hormone replacement therapy. They had a history of moderate to advanced chronic periodontitis, and were undergoing periodontal maintenance therapy. Subjects had no history of myocardial infarction, angina, or stroke. The study was a placebo-controlled, double-blind, two-center (University of Nebraska Medical Center College of Dentistry and Stony Brook University School of Dental Medicine) randomized clinical trial. Only data from Stony Brook subjects were included in this paper, as insufficient amounts of serum remained from Nebraska subjects after completion of the previous biomarker analyses. Fifty-three subjects were randomized at Stony Brook; 46 Stony Brook subjects completed the trial and signed an addendum consent form to conduct additional serum analyses. Serum was not collected from one subject at the 1-year visit; thus, 45 subjects who had been randomly assigned to take placebo (n = 26) or doxycycline hyclate (20 mg, n = 19) tablets twice daily for 2 years were included in the analyses of cholesterol efflux and serum concentrations of apoA-I, apoA-II, and SAA. The study protocol was reviewed and approved by the Stony Brook Institutional Review Board.
Blood samples were drawn at baseline, 1-, and 2-year appointments. Blood (15 ml) was drawn from the antecubital fossa using standard venipuncture technique. The blood was spun at 1,000g in a refrigerated centrifuge for 10 min after remaining at room temperature for 20 min. Serum samples were then aliquoted and frozen at -80°C until analyzed.
Isolation and radiolabeling of LDL Low-density lipoprotein (LDL) was isolated from human citrate plasma as a density cut-off 1.019 \ d \ 1.063 g/ml by sequential ultracentrifugation in a Beckman Ti 50.2 rotor at a speed of 193,000g for 24 h using KBr to adjust the density [19] . Isolated LDL was acetylated in the presence of acetic anhydride [20] and sterile-filtered. Thereafter, acetyl-LDL (acLDL) was labeled by incubating with [1a,2a(n) 3 H]cholesteryl oleate (PerkinElmer, Waltham, MA) dissolved in dimethyl sulfoxide. The specific activity of the [1a,2a(n) 3 H]cholesteryl oleate-acLDL was 18,000 dpm/lg.
Cell culture and loading of the cells with cholesteryl esters
Human THP-1 monocytes were purchased from American Type Culture Collection (ATCC). The monocytes were maintained in RPMI 1640 medium supplemented with 10 % (v/v) fetal bovine serum (FBS) (Lonza, Basel, Switzerland), 25 mM HEPES, 100 U/ml penicillin, and 100 lg/ml streptomycin at 37°C in a humidified atmosphere of 5 % CO 2 . The cells were used for the experiments between passages 7 and 12. Lipoprotein-deficient serum (LPDS; d [ 1.25 g/ml) was prepared from FBS by ultracentrifugation in a TL-100.3 rotor at a speed of 541,000g for 18 h at 10°C in an Optima TL-100 Tabletop Ultracentrifuge (Beckman) using solid KBr to adjust the density [21] , and sterile-filtered prior to use.
To differentiate the cells into macrophages, they were plated onto 24-well plates at a density of 500,000 cells/ml and treated with 100 nM phorbol 12-myristate 13-acetate (PMA) in the growth medium for 72 h. The macrophages were washed twice with PBS and loaded with [1a,2a(n)- 3 H]cholesteryl oleate-acLDL (10 lg of protein/ ml) in RPMI 1640 medium containing 5 % LPDS, 25 mM HEPES, 100 U/ml penicillin, and 100 lg/ml streptomycin for 48 h. The cells were washed twice with PBS and the medium was changed to DMEM supplemented with 25 mM HEPES and the antibiotics.
Cholesterol efflux assay
The ability of the serum samples to remove cholesterol from acLDL-loaded THP-1 macrophages was measured as follows: serum (1 % v/v) from placebo-or SDD-treated subjects was added to triplicate wells containing acLDLloaded macrophages and the cells were incubated for 16 h. The control cells were incubated in the absence of serum to measure the spontaneous cholesterol diffusion. After incubation, the medium was collected and centrifuged to remove any detached cells. The cells were washed twice with PBS and lysed with 0.2 M NaOH. The radioactivity in the medium and cell lysates was analyzed by liquid scintillation counting (Wallac WinSpectral 1414, Wallac, Turku, Finland). Cholesterol efflux was calculated as the percentage of the medium [
3 H] activity of the total [ 3 H] activity (medium ? cells). Efflux values to incubation medium in the absence of serum were subtracted from those in the presence of serum. The experiments were performed in triplicate wells. The samples (baseline, 1-and 2-year) of each patient were measured on the same plate in adjacent wells. Each plate included samples from both placebo and SDD subjects.
Measurement of apoA-I, apoA-II, and SAA ApoA-I was quantified from serum samples by an ELISAbased assay [22] . Of other HDL-associated proteins, the concentrations of apoA-II and SAA were measured with commercial ELISA kits (apoA-II: Abnova, Taipei City, Taiwan; SAA: Invitrogen, Carlsbad, CA, USA). The concentrations of HDL cholesterol, total cholesterol, triglycerides, IL-6, MMP-8, MMP-9, TIMP-1, TNF-a, and hsCRP were measured from the serum samples previously [17] .
Statistical analyses
Analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA, version 9.1.3). These data represent secondary analyses from a randomized clinical trial. Demographic, clinical, and medication use distributions were compared between SDD and placebo groups using a 2-sample t test for continuous measures and a chisquared test for categorical measures. Repeated measurements over time were analyzed using subject-level data. Linear regression models were fitted, using generalized estimating equations methodology to account for the correlation between the repeated measurements for each subject. Changes in the follow-up outcome measures relative to baseline were modeled as a function of the study drug with adjustment for the baseline outcome measure, visit (1-or 2-year), and baseline smoking status (a randomization stratification factor) as independent variables [23] . A natural log transformation was applied to the outcome measure to satisfy linear model assumptions for models of triglyceride and MMP-8 levels. A visit-by-studydrug interaction was investigated. Given the limited power to detect differences in time trends between treatment groups, analyses were stratified by study visit. The distribution of 1-and 2-year changes in the outcome measures relative to baseline was compared to a null value of 0 using a one-sample t test for within-group analyses. The estimated mean change in cholesterol efflux from baseline at a given visit is expressed in the original measurement units, as percentage points, and not as a relative change. Similarly, model estimates of the effect sizes for other measures are expressed in the original measurement units. Linear mixed effects models, with random subject and tooth terms, were used to estimate the standard deviation of baseline site-level periodontal measures.
The primary analysis was intent-to-treat, where data were analyzed according to randomized assignment (SDD = 19; placebo = 26). A secondary, per-protocol analysis included only measurements up to the time point at which lack of protocol adherence occurred (e.g., initiation of significant concomitant medications or pill count adherence rate below 80 %) (SDD = 11; placebo = 14). Pre-specified subgroup analyses were performed based on time since menopause (within or beyond 5 years) and statin use, using tests of interactions in the regression models. No formal adjustment to the alpha level was made for multiple tests performed, as the subgroup analyses are exploratory in nature. Linear regression models were created to describe the associations between serum cholesterol efflux capacity (outcome variable) and other serum measures, which included lipids (cholesterol, triglycerides), proteolytic enzymes (MMP-8, MMP-9, TIMP-1), inflammation markers (TNF-a, IL-6, hsCRP), and HDL-associated proteins (apoA-I, apoA-II, SAA, HDL total protein), at the same visit using a similar modeling approach as previously described to investigate modifying effects of SDD treatment and follow-up time.
Results
The baseline characteristics and medication use of the study subjects are presented in Table 1 . The demographic characteristics, clinical characteristics, and medication use did not differ between SDD and placebo groups.
The results of the cholesterol efflux experiments are illustrated in Fig. 1 . The mean cholesterol efflux % levels at baseline did not differ between the SDD and placebo groups ( Table 2 ). In between-group comparisons, the data were analyzed as to whether the change from baseline differed between the SDD and the placebo groups. Mean cholesterol efflux % levels at the 1-year time point of follow-up were 3.0 percentage points (unit change) higher among SDD subjects compared to the placebo subjects [95 % confidence interval (CI) 0.7-5.3 percentage points, p = 0.010] after adjustment for baseline cholesterol efflux levels and smoking status, while there was no significant difference based on 2-year changes (0.7 percentage point increase associated with SDD, 95 % CI 1.8 decrease to 3.1 increase, p = 0.61). When the change in cholesterol efflux levels from baseline was analyzed for the SDD and the placebo groups separately, SDD subjects demonstrated a significant increase in cholesterol efflux at the 1-and 2-year time points compared to baseline (mean unit change from baseline at 1-year time point: 2.83 percentage points; mean unit change from baseline at 2-year time point: 2.66 percentage points; p \ 0.04 for each) ( Table 2 ; Fig. 1 ). There were no significant changes in cholesterol efflux in the placebo group during this time period.
In addition to cholesterol efflux, we analyzed the concentrations of certain HDL associated proteins. No significant differences in the changes of apoA-I, apoA-II, or SAA levels over the follow-up time between the SDD and the placebo groups were observed (Table 2) . Furthermore, no significant differences were found in HDL cholesterol, total cholesterol, triglyceride, or MMP-8 concentrations between the groups (Table 2 ).
In the subgroup of women more than 5 years postmenopausal, the 1-year changes in cholesterol efflux % levels were 3.96 percentage points higher in the SDD group (n = 11) compared to the placebo group (n = 13) (p = 0.012), although statistically this effect was not different from that seen among women within 5 years of menopause (p = 0.17) ( Table 3) .
The association between cholesterol efflux and certain lipids, inflammation markers, and proteolytic enzymes was studied. The cholesterol efflux capacities of serum were significantly associated with total cholesterol (positive association, at the 2-year visit only) and the proinflammatory cytokine IL-6 (inverse association, among placebo subjects only) ( Table 4 ). There was no association between cholesterol efflux capacity and serum HDL cholesterol, LDL cholesterol, triglyceride, MMP-8, MMP-9, TIMP-1, TNF-a, or hsCRP concentrations.
However, a significant positive association between apoA-I levels and serum cholesterol efflux capacity was demonstrated (regression coefficient 3.54, p = 0.0006) ( Table 4 ). There was no association between apoA-II or SAA levels and cholesterol efflux. Finally, total HDL protein (the sum of apoA-I, apoA-II, and SAA) was positively associated with cholesterol efflux when summarizing across all study visits (regression coefficient 3.49, p = 0.0005) ( Table 4) .
Discussion
In this study, the mean cholesterol efflux capacity of serum samples over the first year of the clinical trial was significantly higher among SDD-treated subjects compared to placebo subjects after adjustment for baseline cholesterol efflux levels and smoking status. However, the difference between SDD patients and placebo patients was not maintained through the second year of the study. The cholesterol efflux capacity of serum was directly associated with the concentration of apoA-I and the sum of apoA-I, apoA-II, and SAA proteins and, in the placebo group only, inversely associated with serum IL-6.
Previous studies have shown that, in addition to its antimicrobial activity, doxycycline also exhibits antiinflammatory and anticollagenase properties [10, 11] . SDD therapy for 6 months lowered the plasma levels of CRP and IL-6, and MMP-9 activity [15] . SDD treatment for 2 years decreased serum hsCRP and MMP-9 levels in the overall population of postmenopausal osteopenic women and increased serum HDL cholesterol levels in a subgroup of women more than 5 years postmenopausal [17] . According to our results, SDD also affects the capacity of serum to remove excess cholesterol from macrophages. Interestingly, SDD treatment especially affected the serum efflux capacity of women more than 5 years postmenopausal.
Based on between-treatment group comparisons, mean cholesterol efflux levels increased significantly over the first year of follow-up for SDD patients relative to placebo patients, while there was no significant difference between treatment groups based on 2-year changes from baseline. When considering within-group comparisons relative to baseline, the increase in cholesterol efflux observed among SDD patients at the 1-year time point was sustained through the 2-year study period. Cholesterol efflux levels were significantly increased at the 1-and 2-year time points, relative to baseline, for SDD subjects. However, there was an increase in mean cholesterol efflux levels, although not statistically significant, in the placebo group at the 2-year time point relative to baseline, rendering the between-treatment group comparison of 2-year changes non-significant. This increase observed among placebo patients may be due to lipid-lowering medications used. Post-baseline initiation of or an increase in the dose of a statin was slightly more common among the placebo than the SDD patients during the course of the 2-year study: three of the placebo patients (12 %) either started a statin or increased the dose after the 6-month visit compared to 0 % of the SDD patients, which may have influenced the results in this relatively small sample. Since the best known promoters of cholesterol efflux are HDL and lipid-poor apoA-I, most efflux studies are carried out using isolated HDL as cholesterol acceptor. However, the serum environment containing the HDL with all its subpopulations in their native proportions and compositions as cholesterol acceptors is physiologically the most relevant one. Naturally, serum's ability to remove cholesterol from macrophage foam cells depends on multiple factors. In addition to lipoprotein subclass distribution and composition, the activities of cholesteryl ester transfer protein (CETP), lecithin-cholesterol acyltransferase (LCAT), and phospholipid transfer protein (PLTP) affect the macrophage cholesterol efflux [24] . We demonstrated that cholesterol efflux was correlated with the concentration of apoA-I and total HDL protein (calculated as the sum of apoA-I, apoA-II, and SAA). We did not observe a correlation between serum HDL cholesterol levels and cholesterol efflux. Importantly, however, there was a negative correlation between serum IL-6 and cholesterol efflux among placebo subjects, which is in agreement with our earlier study where cholesterol efflux had a negative association with CRP levels in periodontitis patients [9] . The present correlation with IL-6 was not observed among subjects treated with SDD, which is logical since this treatment has an effect on systemic inflammation [17] .
HDL is a heterogeneous population of particles that differ in particle size, charge, and lipid/protein composition. The functional capacity of HDL may vary significantly among these subpopulations [25] . In this context, our study was limited since the composition or functional capacity of HDL or its subclasses was not determined, and neither were the activities of major HDLmodifying factors, such as CETP, LCAT, or PLTP. Even though there was an association between cholesterol efflux capacity and apoA-I concentration, the modifying effect of SDD on cholesterol efflux of serum could not be explained by the changes in apoA-I levels. Thus, the detailed mechanisms responsible for the increase of cholesterol efflux during SDD therapy require further investigation.
Other limitations of our study include the small sample size and the study population being comprised of women only. The potential effect of SDD on men should be studied separately.
It has been suggested [26, 27] that plasma is better than serum in analyzing circulating MMPs and TIMPs, as blood cells, platelets, and the coagulation process contribute to the concentrations of MMPs and TIMPs during serum preparation. The MMP-8, MMP-9, and TIMP-1 concentrations that were analyzed in this study were measured from serum samples [17] . MMP-8 concentrations between these two sample materials have a strong correlation with each other [28] and particularly serum MMP-8 levels associate with future CVD events [29, 30] .
Patients with chronic periodontitis suffer from lowgrade systemic inflammation, as reflected by elevated levels of serum inflammation markers [31] . The levels of HDL cholesterol and apoA-I are decreased during both acute and chronic inflammations [32, 33] , such as periodontitis. Periodontitis causes changes in HDL metabolism and decreases its anti-atherogenic potency and cholesterol efflux capacity [9] . Keeping in mind that five out of ten adults display signs of chronic periodontitis, their therapy increased the cholesterol efflux capacity of serum to an even greater extent among women who were more than 5 years postmenopausal. In previous reports, it was found that SDD also decreased biomarkers of systemic inflammation (hsCRP [15, 17] and IL-6 [15] ) and mediators of atheromatous plaque destabilization (MMP-9 [15, 17] ), and increased cardio-protective HDL cholesterol in a subgroup of women more than 5 years postmenopausal [17] . The results from this and the previous studies suggest that SDD therapy may reduce the risk of cardiovascular disease in this vulnerable group of postmenopausal women with significantly reduced protective endogenous estrogen levels.
